Skin immune biomarker predicts the development of AD in the pediatric population
With a prevalence of 15-20%, atopic dermatitis (AD) is the most common skin disease in the pediatric population. At EADV 2022, The Barrier dysfunction in Atopic newBorns (BABY) study is ready to present results suggesting an essential role of immune biomarkers in predicting the development of AD during the first two years of life.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
